Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28883207 | 0.84 | MAPT (0.66) | MAPTALDH1A1GAARAB9ACYP1A2 | |
| SCHEMBL5432263 | 0.83 | MAPT (0.69) | MAPTALDH1A1GAARAB9ACYP1A2 | |
| SCHEMBL356986 | 0.82 | MAPT (0.68) | MAPTALDH1A1RAB9ACYP1A2KMT2A | |
| SCHEMBL30933151 | 0.82 | MAPT (0.68) | MAPTALDH1A1RAB9ACYP1A2KMT2A | |
| SCHEMBL6138093 | 0.82 | MAPT (0.58) | MAPTALDH1A1GAARAB9ACYP1A2 | |
| SCHEMBL4047674 | 0.80 | KMT2A (0.76) | MAPTALDH1A1GAACYP1A2KMT2A | |
| SCHEMBL3068048 | 0.79 | HTR3E (0.61) | MAPTALDH1A1GAARAB9ACYP1A2 | |
| SCHEMBL5263564 | 0.78 | KMT2A (0.53) | ALDH1A1CYP1A2KMT2ATP53HSD17B10 | |
| SCHEMBL6716900 | 0.78 | MAPT (0.62) | MAPTALDH1A1GAARAB9ACYP1A2 | |
| SCHEMBL5521712 | 0.77 | IDO1 (0.67) | MAPTALDH1A1GAARAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123585-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230114091-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230108452-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP | 2023-04-06 | — | — | US | disclosed |
| US-20230092404-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP | 2023-03-23 | — | — | US | disclosed |
| US-20230083689-A1 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | MERCK SHARP & DOHME LLC | 2023-03-16 | — | — | US | disclosed |
| EP-3706742-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4076452-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20050288294-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| US-20050228003-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| US-20050182256-A1 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative | MERCK & CO., INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050176737-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| US-20050171122-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-04 | — | — | US | disclosed |
| US-20050159422-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-07-21 | — | — | US | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050032817-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung | MERCK SHARP & DOHME CORP. | 2005-02-10 | — | — | US | disclosed |
| US-20040259826-A1 | Mitotic kinesin inhibitors | MERCK & CO., INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114091-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MAPT 4571/4885ALDH1A1 1341/4885GAA 3202/4885 |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | DPYD, TYMP, TK1 | MAPT 4103/4885ALDH1A1 436/4885GAA 2631/4885 |
| US-20050288294-A1 | Inhibitors of akt activity | AKT2, AKT1, AKT3 | MAPT 2400/4885ALDH1A1 3746/4885GAA 1547/4885 |
| US-20040259826-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | MAPT 309/4885ALDH1A1 2572/4885GAA 898/4885 |
| US-20230108452-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MAPT 4638/4885ALDH1A1 2223/4885GAA 3489/4885 |
| US-20050171122-A1 | Mitotic kinesin inhibitors | KIF5B, KIFC1, KIF2C | MAPT 239/4885ALDH1A1 2384/4885GAA 1295/4885 |
| US-20050032817-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 3-benzyl-2-(1-{(4-bromobenzyl)[2-(dimethylamino)ethyl]amino}propyl)furo[2,3-d]pyrimidin-4(3H)-one; antiproliferative and -carcinogenic agents; side effects reduction; cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung | KIF2C, KIFC1, KIF5B | MAPT 741/4885ALDH1A1 1544/4885GAA 1831/4885 |
| US-20050176737-A1 | Mitotic kinesin inhibitors | KIF5B, KIFC1, KIF2C | MAPT 239/4885ALDH1A1 2384/4885GAA 1295/4885 |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | APP, BACE1, BACE2 | MAPT 10/4885ALDH1A1 2224/4885GAA 50/4885 |
| US-20050159422-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | MAPT 2652/4885ALDH1A1 3729/4885GAA 793/4885 |
| US-20050182256-A1 | 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; antiproliferative | PLK1, AKT2, SKP2 | MAPT 2622/4885ALDH1A1 2068/4885GAA 1832/4885 |
| US-20230083689-A1 | METHODS FOR TREATING CANCER WITH A WEE1 INHIBITOR | WEE1, WEE2, TP53 | MAPT 3848/4885ALDH1A1 2947/4885GAA 2234/4885 |
| US-20050228003-A1 | Mitotic kinesin inhibitors | KIF5B, KIF18B, KIFC1 | MAPT 291/4885ALDH1A1 2640/4885GAA 1348/4885 |
| US-20230092404-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MAPT 4575/4885ALDH1A1 2036/4885GAA 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.